Boceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Boceprevir is not indicated as monotherapy. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed
Boceprevir is a NS3/4a protease inhibitor used to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS4A, NS4B, NS5A and NS5B). Boceprevir covalently but reversibly binds the serine (S139) resiude in the active site via a (α)-ketoamide functional group. This inhibits the proteolytic acitvity of the HCV 1a and 1b encoded enzyme.
- Primary indication
- Boceprevir, when used in combination with DB00811, DB00008, and DB00022 is indicated for use in the treatment of chronic HCV genotype 1 infection in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C27H45N5O5 · 519.6767 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2011
- Code names
- EBP-520 · SCH-503034
Resolves to
LHHCSNFAOIFYRV-DOVBMPENSA-NSMILES[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)CWhat you can answer from here — as of January 29, 2025
Which drugs share a target with Boceprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account